Tvardi Therapeutics (NASDAQ:TVRD) Rating Increased to Overweight at Piper Sandler

Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by equities research analysts at Piper Sandler from a “neutral” rating to an “overweight” rating in a research report issued to clients and investors on Wednesday. The brokerage currently has a $13.00 target price on the stock. Piper Sandler’s target price points to a potential upside of 166.61% from the company’s current price.

Several other analysts have also commented on the company. UBS Group raised Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective on the stock in a report on Wednesday. Wall Street Zen lowered Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 4th. BTIG Research reissued a “buy” rating and issued a $15.00 price target on shares of Tvardi Therapeutics in a research note on Tuesday. HC Wainwright assumed coverage on shares of Tvardi Therapeutics in a report on Monday, June 8th. They issued a “buy” rating and a $9.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, April 10th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $24.29.

Tvardi Therapeutics Trading Up 57.3%

TVRD traded up $1.78 on Wednesday, reaching $4.88. The stock had a trading volume of 35,400,473 shares, compared to its average volume of 923,919. The business’s 50-day moving average price is $3.05 and its two-hundred day moving average price is $3.52. The company has a market cap of $45.74 million, a P/E ratio of -1.57 and a beta of 0.39. Tvardi Therapeutics has a 12-month low of $1.50 and a 12-month high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its earnings results on Friday, May 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.08). As a group, analysts predict that Tvardi Therapeutics will post -2.39 earnings per share for the current year.

Institutional Trading of Tvardi Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Arax Advisory Partners raised its holdings in shares of Tvardi Therapeutics by 277.2% during the 4th quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock worth $36,000 after acquiring an additional 6,173 shares during the period. JPMorgan Chase & Co. acquired a new stake in Tvardi Therapeutics during the second quarter worth about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Tvardi Therapeutics during the second quarter worth about $43,000. HRT Financial LP acquired a new position in Tvardi Therapeutics in the 4th quarter valued at about $47,000. Finally, XTX Topco Ltd purchased a new stake in shares of Tvardi Therapeutics in the 4th quarter valued at approximately $55,000. 44.66% of the stock is currently owned by hedge funds and other institutional investors.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.